Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year Low – Should You Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $25.46 and last traded at $25.54, with a volume of 290193 shares changing hands. The stock had previously closed at $26.44.

Analysts Set New Price Targets

COLL has been the subject of a number of research reports. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Needham & Company LLC dropped their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays decreased their target price on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Collegium Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The firm has a market cap of $825.29 million, a price-to-earnings ratio of 20.44 and a beta of 0.73. The stock’s fifty day moving average price is $32.96 and its 200-day moving average price is $35.06.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. During the same quarter last year, the business posted $1.68 EPS. The company’s revenue was up 6.3% on a year-over-year basis. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of COLL. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $61,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.